These findings suggest that ETAST detection via TATAN activation could serve as an independent predictive marker of immunotherapy efficacy in patients with NSCLC, distinct from known markers such as PD‐L1 expression and pre‐treatment NLR. This evidence concerns the gene CD274 and non-small cell lung carcinoma.